What happened
SCYNEXIS, Inc. (NASDAQ: SCYX) won a cost-share contract from the U.S. Biomedical Advanced Research and Development Authority to advance SCY-247, an experimental antifungal designed for serious invasive infections. The initial base period provides about $18.5 million for oral and intravenous versions of the drug to move into a Phase 2 trial in invasive candidiasis.
SCY-247 is meant to inhibit glucan synthase, an established fungal target, while offering both hospital-use intravenous dosing and an oral option. The program has FDA Fast Track, Qualified Infectious Disease Product and Orphan Drug designations. Those labels can help development, but they do not establish safety, efficacy or approval.
Why it matters
That base still matters. SCYNEXIS, Inc. (NASDAQ: SCYX) ended June with $71.1 million of cash, cash equivalents and investments after raising $36.9 million net in a March private placement. BARDA now absorbs eligible SCY-247 costs, including direct and administrative expenses, while the company says its share fits inside the existing plan and its runway into 2029 is unchanged.
The evidence that this model can work is limited but real. BREXAFEMME, an approved drug from the same antifungal class, is licensed to GSK plc (NYSE: GSK). SCY-247 itself remains experimental, and the BARDA award is not product revenue or an FDA endorsement. The cost-share structure also leaves some expense with SCYNEXIS, Inc. (NASDAQ: SCYX), while previously issued shares and warrants keep dilution in the countercase.
What's next
First watch the completed intravenous Phase 1 analysis, then the design and start of the Phase 2 candidiasis trial. Later BARDA option exercises would show that the government judged the program worth funding beyond the base period.
The thesis strengthens if clean clinical data unlock those options without another dilutive raise. It weakens if safety, efficacy or regulatory problems delay Phase 2, if BARDA declines later options, or if SCYNEXIS, Inc. (NASDAQ: SCYX) must fund materially more of the program than the current plan assumes.
Sources
- SCYNEXIS, Inc. (NASDAQ: SCYX) BARDA contract release — Company-issued release published September 28, 2026. Base-period amount, option-inclusive ceiling, cost-share terms, development scope and program status.
- SCYNEXIS, Inc. (NASDAQ: SCYX) second-quarter 2026 update — June liquidity, March private-placement proceeds, warrants, development milestones and management cash-runway guidance.
- SCYNEXIS, Inc. (NASDAQ: SCYX) June 2026 Form 10-Q — Filed balance sheet, share count, cash use, program descriptions and financing disclosures for the quarter ended June 30, 2026.
- StockAnalysis SCYNEXIS, Inc. (NASDAQ: SCYX) price history — Checked September 29, 2026. September 28 close of $4.62 and a calculated 20-session average of 441,482 shares using completed sessions through September 28. Data source shown as S&P Global Market Intelligence.
- Photo: Candida albicans PHIL 3192 lores by CDC and Dr. William Kaplan — CDC laboratory file photograph created in 1969. Generic fungal-culture context. It does not depict SCY-247, SCYNEXIS, Inc. (NASDAQ: SCYX) facilities or a clinical trial. Cropped to 16:9 for display.
- Photo license: United States public domain — Creator credit: CDC and Dr. William Kaplan. The Wikimedia Commons file page identifies the work as a U.S. federal-government work in the public domain.
Read the full OptimistFi thesis on SCYNEXIS, Inc.: https://optimistfi.com/stocks/SCYX
See what would break the SCYNEXIS, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full SCYNEXIS, Inc. investment case, its status and the next test to watch live on the SCYNEXIS, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
